Analysts at Jefferies have come up with a list of four pharmaceuticals stocks that may be good investments for a time of uncertainty in global markets.
General Electric ended Procter & Gamble's run as the worst performing Dow stock last week. GE shares dropped more than 1% for the week.
The worst-performing Dow 30 stock for the year to date remains consumer products giant Procter & Gamble.
It’s no surprise that it was only a matter of time before the usage and storage of big data and analytics would come to the health care sector, and many of the…
Procter & Gamble shares added more than 1% last week but that was not enough to allow the consumer products giant to relinquish its position as the worst performing Dow stock of…
Exxon Mobil, Chevron, Johnson & Johnson, and JPMorgan led the Dow to a lower close Thursday.
The Dow's worst performing stock for the past 5 weeks has been consumer products giant Procter & Gamble. Last week was an uneventful one for the company as the stock ticked up…
This year marks the 54th annual meeting of the American Society of Clinical Oncology, the world’s largest clinical cancer conference.
The U.S. Food and Drug Administration on Thursday published a list of brand-name drug companies that the agency has received complaints against for obstructing development of generic versions of their drugs.
Cisco, Walmart, Merck, and Johnson & Johnson were among the leading losers on the Dow Thursday.
Procter & Gamble was able to add a bit to its share price last week, but not enough for it to shake its position as the worst performing Dow stock of 2018.
The Dow is set to close with a modest gain Friday led by Verizon, Merck, UnitedHealth, and Johnson & Johnson.
Procter & Gamble is holding on to its ranking as the worst-performing stock among the 30 equities that comprise the Dow Jones Industrial Average.
Verizon, Travelers, Johnson & Johnson, and McDonald's weighed on the Dow Wednesday.
Johnson & Johnson just delivered yet another dividend hike. The company previously had committed to increasing its dividends over and over.
Jon C. Ogg 
